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Abstract
Background: Self-assembly is a common theme in proteins of unrelated sequences or functions. The human papillomavirus
E7 oncoprotein is an extended dimer with an intrinsically disordered domain, that can form large spherical oligomers. These
are the major species in the cytosol of HPV transformed and cancerous cells. E7 binds to a large number of targets, some of
which lead to cell transformation. Thus, the assembly process not only is of biological relevance, but represents a model
system to investigate a widely distributed mechanism.
Methodology/Principal Findings: Using various techniques, we monitored changes in secondary, tertiary and quaternary
structure in a time course manner. By applying a robust kinetic model developed by Zlotnik, we determined the slow
formation of a monomeric ‘‘Z-nucleus’’ after zinc removal, followed by an elongation phase consisting of sequential second-
order events whereby one monomer is added at a time. This elongation process takes place at a strikingly slow overall
average rate of one monomer added every 28 seconds at 20 mM protein concentration, strongly suggesting either a
rearrangement of the growing complex after binding of each monomer or the existence of a ‘‘conformation editing’’
mechanism through which the monomer binds and releases until the appropriate conformation is adopted. The
oligomerization determinant lies within its small 5 kDa C-terminal globular domain and, remarkably, the E7 N-terminal
intrinsically disordered domain stabilizes the oligomer, preventing an insoluble amyloid route.
Conclusion: We described a controlled ordered mechanism with features in common with soluble amyloid precursors,
chaperones, and other spherical oligomers, thus sharing determining factors for symmetry, size and shape. In addition, such
a controlled and discrete polymerization reaction provides a valuable tool for nanotechnological applications. Finally, its
increased immunogenicity related to its supramolecular structure is the basis for the development of a promising
therapeutic vaccine candidate for treating HPV cancerous lesions.
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Introduction
It is well established that proteins have no unique conformation;
in fact, protein conformation in solution differs depending on the
chemical and physical parameters under which they are studied.
The different conformations acquired may include the native
protein ensemble, soluble oligomers of different morphology, and
insoluble amyloid fibrils, among other structures.
Amyloid like structures have been observed in vitro from disease-
associated and disease-unrelated proteins and peptides, and
despite having different folding topologies and characteristics,
they show common properties, such as the formation of spherical
soluble oligomeric precursors [1,2]. However, the formation of
spherical soluble oligomers in biological systems is not limited to
the formation of amyloid fibril precursors but also to other relevant
systems like chaperone proteins [3,4], viral origin binding proteins
[5,6], spherical nanoclusters, ‘‘Blackberry’’ type supramolecular
structures or self assembly macroions [7]. Besides morphological
and structural similarities between these different non-related
oligomers, they can be grouped based on their kinetic assembly
mechanism. In addition, the formation of viral capsids follows a
similar kinetic mechanism [8]. Kinetic mechanisms of protein self-
assembly of closed spherical oligomers is poorly understood due to
experimental difficulties on assaying an assembling system that
involves different (and at the same time similar, i.e., the same
subunit) species and time scales.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36457The human papillomavirus is a small DNA tumor virus, the
causative agent for uterine cervix cancer and other types of
cancers of high impact on health. They have two main
oncoproteins, E6 and E7, which are responsible for tumorigenic
progression, with counterparts in other small DNA tumor viruses
that operate by forcing cells into S-phase in order to use the cell
machinery for replication of their viral genomes [9,10]. E7 is the
major transforming protein in HPV and is under the repressive
control of the E2 master regulator [11]. The E2 open reading
frame is disrupted upon integration of the viral genome to the host
chromosome, and thus, in the absence of the repressor, the E7
oncoprotein expression becomes deregulated, promoting transfor-
mation [12]. We and others have shown that there is a direct
interaction between E2 and E7 [13,14], and careful biochemical
investigation led us to propose a finely tuned mechanism for
regulating the relative protein levels of E2 and E7 and effects on
the balance between repression and transformation, based on
oligomerization and aggregation of the complexes formed [14].
In this work we investigate the particular case of the
oligomerization mechanism of E7 protein from human papillo-
mavirus as a model for protein self-assembly [15,16]. HPV16 E7 is
a 98-amino acid protein bearing two domains, the N-terminal,
E7N, and the C-Terminal, E7C, of 40 and 58 aminoacids,
respectively. E7 was initially described as an extended dimer,
which can be described at least in part as an intrinsically
disordered protein (IDP) [17,18]. The intrinsically disordered
property was found to map to the E7N region, which was defined
as a bona fide highly conserved domain, despite lacking canonical
secondary or tertiary structure. This, together with the absence of
folding cooperativity, defines it as an intrinsically disordered
domain (IDD) [19]. E7C is a dimeric folded domain that contains
two highly conserved CXXC motifs which coordinate one mol of
Zn per mol of protein [17,20]. Structures of E7C from other
related strains showed a well-structure domain with a non classical
Zn finger-type arrangement [21,22]. This metal was shown to be
fundamental for maintaining the E7C fold and as a prerequisite
for dimerization [22].
In a previous work, we demonstrated that E7 can self-assemble
in vitro into spherical oligomers (E7SOs) when the protein Zn is
removed by a chelating agent [15]. E7SOs are highly stable, they
show homogeneous size and morphology, and bind to dyes like
Congo Red and thioflavin T, reflecting the presence of a repetitive
b-sheet structure in the non-fibrillar self-assembly of E7SOs.
Interestingly, it was shown that E7SOs, and not the E7 dimer, can
bind and prevent aggregation of non-viral proteins normally used
as standard chaperone substrates. The topological arrangement of
these oligomers indicate that the E7C forms the oligomerization
core, while the E7N IDP domain faces the solvent [16].
E7 has been reported to have nuclear and cytoplamatic
localization [23,24,25,26]. We have shown that the oligomeric
forms of E7 are in fact present in model HPV-transformed cell
lines and cancerous tissue in cell, with cytoplasmic localization,
while the E7 dimer-monomer shows nuclear localization [27]. In
addition, we found that the cytosolic oligomer represents the
majority of the E7 protein in these cells. Although the precise
nature of these cellular oligomers cannot be determined, the
conformation repetitive b-sheet structure was confirmed by co-
localization of thioflavin-S staining and E7 in inmunofluorescence
experiments [27]. Altogether, these results provide a strong
biological relevance for the investigation of this assembly
mechanism in connection with the transformation properties of
this prototypic viral oncoprotein.
The E7SOs display a non-reversible and complete assembly
process with an optimal time-scale to be probed in detail with
different spectroscopic and biophysical techniques. In this work,
we present a kinetic dissection of the E7SOs assembly mechanism.
We show that the reaction can be analyzed by the application of
the kinetic model proposed by Zlotnick et al [28]. The reaction is
triggered by zinc removal, progresses through a lag phase into an
elongation phase, to yield the final stable soluble complex. We
elucidated the intermediate size and the different structural events
involved in E7 assembly process: E7C is the oligomerization
domain and the E7N intrinsically disordered domain provides
solubility and prevents progression into an insoluble fibrillar route.
Due to the dynamic nature of the process, the ability to control
it can be particularly in pathological cases in order to target the
assembly as a therapeutic strategy [29,30,31,32] and in nanotech-
nology applications in order to design suitable disposals of desired
size [33,34].
Results
Time Course Events in E7SOs Assembly
As an initial approach to investigate the assembly mechanism of
the E7SOs we analyzed the time course events using different
spectroscopic probes. As we previously showed, the formation of
the oligomers is accompanied by a change in secondary structure,
as judged by the far UV CD spectra [15,17]. The reaction is
triggered by the addition of EDTA to the folded dimeric form of
E7 (E72), and spectra at different times show two points of
maximum signal change, one around 202 nm and the other at
216 nm (Figure 1A). Although only two species (folded dimer and
oligomer product) are observed at the equilibrium, the spectrum at
3 minutes showed a decrease in the 220 nm region. In fact, when
we monitored the change in ellipticity with time at 202 nm and
216 nm, a biphasic behavior was observed at the two wavelengths
(Figure 1B, 216 nm is shown). A first rearrangement is over by 300
seconds, followed by a slower second transition with a half-life of
,11 minutes (Fig. 1B).
The change in tertiary structure was followed by monitoring the
intrinsic fluorescence change corresponding to tyrosine residues.
There is a slow decrease in fluorescence with an apparent t1/2 ,11
minutes, reaching a steady state at 60 minutes (Figure 1B). Taking
advantage of the amyloid-like properties of E7SOs we have
previously described [15], we aimed at monitoring the formation
of repetitive b-sheet upon assembly of the oligomer, as a probe for
quaternary structure. We analyzed the kinetics by adding
thioflavin T (ThT) and measuring the change in fluorescence
with time. For this experiment, we determined that the binding of
the dye takes place within the dead time of the experiment (15
seconds, not shown), much faster than that of the oligomerization
itself, a noticeably slow process. The process shows a lag phase of
,250 seconds, not observed in the tertiary structure monitored by
tyrosine fluorescence (Figure 1B), but coincident with the first
secondary structure rearrangement (Figure 1C). This lag phase is
followed by a slow increase in ThT binding with a half-life
approximately of 10 minutes at this protein concentration, which
is in overall agreement with the tertiary structure rearrangement
observed by tyrosine fluorescence change. In any case, the lag
phase is a strong indicator of an intermediate species being
accumulated.
As an additional probe, we tested the evolution of the binding of
8-anilino, 1-naphtalene sulfonate (ANS) with time. ANS binds to
hydrophobic environments or cavities, when these are accessible to
the solvent, constituting an alternative probe for evaluating the
formation of tertiary and quaternary structure [35]. Figure 1C
shows that the ANS fluorescence change is superimposable to the
ThT binding trace, strongly suggesting that they are monitoring
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formation, and coincident with the slow CD rearrangement. It
should be stressed that no detectable fast phase is observed within
the experimental dead time, in any of the probes used.
The extremely slow nature of the process and the presence of
multiple phases, allow for the determination of the size increase as
the reaction proceeds. For this purpose, we measured the time
course assembly of the E7SOs by dynamic light scattering (DLS).
The hydrodynamic diameter (Dh) of E7 species was measured
before the addition of EDTA and after the stationary state was
reached (Figure 2A, 2B). The species at time zero that corresponds
to E7 dimer yields a Dh=6.860.8 nm, larger than the expected
size for a globular protein of 196 amino acids (4.4 nm [36]). This
observation is in excellent agreement with previous results where
we determined an extended conformation of E72 in solution,
originated from its intrinsically disordered nature [17]. The
hydrodynamic diameter of E7SOs was measured in the plateau
of the reaction, yielding a Dh,E7SOs of 16.962.2 nm (Figure 2B).
If we superimpose the DLS data with CD data, we can conclude
that changes in tertiary and quaternary structure indeed take place
in parallel (Figure 2C). However, since ThT fluorescence (similar
to ANS) yields a much better signal-to-noise ratio, and is
superimposable with CD (Figure 2C), we use ThT for subsequent
experiments which require fiting the data to a mathematical
model.
To further investigate the size of the species formed in the lag
phase, we measured the diameter at 1 and 4 minutes, with Dh
values of 5.960.7 nm and 8.761.4 nm, respectively. The
experimental value Dh,1min is in accordance with the predicted
value of a denatured chain of the same length than the E7
monomer (6 nm [36]). However, as Dh,1min and Dh,4min are
similar to the diameter found for the E7 dimer (6.860.8 nm)
within experimental error, we cannot distinguish between
monomer or dimer at this ‘‘pre-oligomerization’’ phase. Never-
theless, these species are clearly smaller than the endpoint
oligomers (16.962.2 nm), indicating that the slow phase corre-
sponds to the oligomerization event.
Figure 1. Assembly Kinetics of E7SOs followed by different
spectroscopy probes. (A) CD spectra obtained at different times
during E7SOs assembly. CD spectrum of E72 before addition of EDTA
(full line) and CD spectra of E7 at different times after EDTA addition, at
3 minutes (dashed line), 15 minutes (full line with rectangles) and at 60
minutes (dashed and dotted line). (B) Kinetics of E7SOs assembly
monitored by circular dichroism and tyrosine fluorescence. Far-UV CD at
216 nm (black circles) and tyrosine fluorescence (full line); both
experiments were carried out at the same protein concentration and
triggered by the addition of 1.0 mM EDTA. (C) Kinetics of E7SOs
assembly followed by Thioflavin T fluorescence (black line) and ANS
fluorescence (grey line); both experiments were carried out at the same
protein concentration and triggered by the addition of 1.0 mM EDTA
right before beginning the measurement.
doi:10.1371/journal.pone.0036457.g001
Figure 2. Size distribution measured by DLS. (A) Size distribution
profile of E7 dimer before addition EDTA. (B) Size distribution profile of
E7SOs. (C) Kinetics of E7SOs formation followed by DLS (black circles
with error bars), where the initial time correspond to E7 dimer before
the addition of EDTA, kinetics followed by Th T fluorescence (black line)
and far-UV CD at 216 nm (black circles). The experiments were carried
out at the same protein concentration and triggered by the addition of
1.0 mM EDTA.
doi:10.1371/journal.pone.0036457.g002
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Coordination of Zn is essential for folding of the C-terminal
domain of E7, and a prerequisite for dimerization [22]. Since
oligomerization is triggered by the removal of Zn upon addition of
a chelating agent, we wanted to asses how a compound with
different metal affinity might affect the reaction and its phases. We
used N,N,N9,N9-tetrakis(2-pyridyl-methyl)ethylenediamine
(TPEN) a chelator with a two order of magnitude higher affinity
constant for Zinc with respect to EDTA [37]. TPEN has specificity
for heavy metals like Zn (Ka 10
16 M







–1, respectively), providing a
higher selectivity [38].
We monitored the oligomerization kinetics followed by ThT
fluorescence for both chelators (Figure 3). CD spectra and DLS
confirmed that the final oligomers obtained after the addition of
both chelators are similar (not shown). Figure 3 shows that TPEN
noticeably shortens the lag phase, although the slow oligomeriza-
tion phase appears unaffected (t1/2(EDTA),8 min y t1/2(TPEN)
,6 min), but clearly the largest effect is observed in the lag phase.
The disappearance of the lag phase is likely to arise from the
higher affinity of TPEN for zinc, which accelerates the formation
of the metal-free intermediate, without affecting the polymeriza-
tion phase. This strongly suggests that the rate-limiting step is the
sequential break of the individual zinc-thiolate bonds from the
protein, ultimately leading to complete metal removal.
Next, we wanted to address the possibility of removing the zinc
atom by blocking the cysteine groups instead of chelating the
metal. For this, we made use of p-hydroxymercuriphenylsulfonate
(PMPS) an organomercurial compound which reacts instantly with
cysteine residues, displacing the metal from the high-affinity Zn
coordinating center. The release of the zinc atom is reported
spectroscopically by the formation of the complex of the metal
with the metallochromic reporter e 4-(2-pyridylazo) resorcinol
(PAR). When PMPS is added to a mixture of PAR with E7, the
absorbance increase reports the stoichiometric formation of a
Zn(PAR)2 complex, after the release of the metal from the protein
coordination centre (Figure 4A). The PMPS modified apo-E7 is
stable in solution but with a significant secondary structure
change, namely, loss of alpha helical content as judged by FAR-
UV CD spectrum (Figure 4B). This species does not form
oligomers, even after prolonged incubation periods, and this can
be confirmed by DLS which yields an hydrodynamic diameter of
9.761.7 nm (Figure 4A, inset DLS).
The addition of a reducing agent such as DTT should instantly
break the PMPS-cysteine bonds, and the recapturing of the metal
would indicate that the protein remains in a competent
conformation for restoring the tetrahedral coordination of the
zinc. This is the case for E7-PMPS, where addition of DTT
instantly and stoichiometrically decreases the PAR-zinc absor-
bance back to the untreated baseline value (Figure 4A). An
important implication of this result is that removal of zinc only
may not be enough to trigger polymerization; a conformational
factor involving the cysteines is required for the formation of the
oligomerization competent intermediate. Similar results were
found when cysteines were modified with iodoacetamide (data
not shown).
Kinetic Model for the E7SOs Assembly Mechanism
The assembly of a spherical oligomer or a capsid can take place
through multiple elementary reactions either combined or
fragmented in intermediate species of different shapes and masses.
Zlotnick et al developed simple and general models that can be
applied to the formation of viral capsids or of any spherical
polymer [28,39]. These assembly processes can be described in
terms of a cascade of low-order association reactions, which
display a sigmoideal kinetic behavior with a lag phase that
precedes the elongation phase to yield the final oligomer at the
stationary state. Two models were proposed for interpreting the
assembly mechanisms: the equilibrium assembly model (EQ) and
the kinetically limited assembly (KL). The details of each model
were explained in detail [28], but we briefly summarize the
grounds for our choice of the model. We shall first clarify that the
term ‘‘nucleation’’ used by Zlotnik is different from classical
nucleation as observed in linear polymerization and typical
amyloid routes [40], therefore, in order to avoid confusion, we
name it ‘‘Z-nucleation’’. The EQ model: i) does not require Z-
nucleation, ii) requires low interaction energy among the
monomers, iii) is susceptible to kinetic traps because of multiple
parallel assembly initiation processes, and iv) the stability of the
final assembly must be low. Z-nucleation is required in the KL
model, and there is no restriction to the association energies or the
stability of the final assembly. Z-nucleation refers to the formation
of the minimum assembly competent unit, not to intermediate size
oligomers, referred as ‘‘nucleus’’ in classical amyloid fiber models.
More importantly, the KL model is robust to kinetic traps, which
translates into a completed reaction and an homogeneous final
assembly. Since these premises are satisfied in the reaction we
describe, we apply the KL model for the analysis of our
experimental data.
In the KL model, the Z-nucleation size and the elongation
reaction order can be analyzed by spectroscopic probes [28]. We
studied the E7SOs assembly monitoring the ThT fluorescence
change that reports the oligomerization concomitant with the
formation of repetitive b-sheet strands (see Figure 2C). We verified
that the increase in ThT fluorescence is linearly dependent on
protein concentration in the range used in these experiments (not
shown).
The concentration dependence of the assembly process shows
the concentration dependence of the rate and the extent of E7SOs
formation (Figure 5A). In addition, two important parameters can
be obtained from the time traces of oligomer formation at different
protein concentrations based on the KL model. This model
assumes that once formed, each z-nucleus should quickly form
E7SOs and, therefore, the rate of the E7SOs formation is equal to
the overall rate of z-nucleus production. The ratio [E7SOs]/[E7]
is obtained at a given time within the linear elongation phase at
each concentration. The z-nucleus size n, i.e., the number of
Figure 3. Assembly of E7SOs triggered by different Zn
chelators. Kinetics assays were followed by Th T fluorescence. The
reaction was started with different chelating metal, 1.0 mM EDTA (grey
full line) and 1.0 mM TPEN (black full line) right before beginning the
measurement. The protein concentration was 15 mM in both experi-
ments.
doi:10.1371/journal.pone.0036457.g003
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½E7SOs ~k½E71free 
n ð1Þ
The double log plot allows for the determination of the z-
nucleus size, in this case n=1.260.2. This number is an
average obtained from the plots at 4 different times (Figure 5B),
indicating that the initial z-nucleus is monomer. As we had
previously determined the ‘‘apo’’ nature of this species from the
TPEN experiment (Figure 3), we can conclude that the z-
nucleus is an apo-monomer. In support to this, the lag phase
does not change significantly with concentration (Figure 5A) and
is abolished by the stronger chelator TPEN (Figure 3). The
weak dissociation constant of the E7 dimer (1 mM, [41]) implies
that the dissociation rate will be much faster than the slow
events related to the metal removal by EDTA, and the
monomeric species (the starting point of the reaction) is
instantly available (fast pre-equilibrium). Therefore, the apo-
monomer acts as the building block for the assembly.
According to the model, the order of reaction of the elongation
process was determined from the slope of the linear elongation
phase, representing the rate of oligomerization, plotted against the
initial concentration [E7]i [28,42]. This concentration dependence
was measured in a log-log plot for six different concentrations; the
slope was 2.360.3, indicating a second-order elongation reaction
(Figure 5C). This result suggests a rapid sequential addition of
single monomers as the pathway for E7SOs assembly proceeds.
However, since i) the second-order addition is coupled to a slow
conformational rearrangement, ii) the number of subunits was
previously estimated to be 70 [15], iii) the overall process is
completed in 2000 seconds at 20 mM, the overall average rate,
calculated from the linear phase, is one monomer added every
,28 seconds.
The C-terminal Domain of E7 Drives the Oligomerization
that Leads Fibril Formation in the Absence of the N-
terminal Domain
E7 is a modular protein in all HPV types, where the C-terminal
E7 domain (E7C) is the dimerization and Zn binding domain and
the N-terminal IDD (Intrinsically Disordered Domain) domain
displays different biologically relevant interaction sites. As an
alternative way to probe the assembly mechanism and the regions
involved, we decided to investigate the oligomerization of the
isolated E7C by removing the N-terminal intrinsically disordered
domain (IDD), by expressing the truncated form recombinantly.
E7C is a globular dimeric domain with a CD spectrum typical
of high a-helical content, with minima at 208 nm and 222 nm
(Figure 6A) [21,22]. The spectrum obtained after incubation with
EDTA for approximately 2 hours indicates an increased propor-
tion of b-sheet structure, with a broad minimum at around
216 nm. Further overnight incubation shows the loss of the signal,
caused by insoluble aggregation. Similar to the full-length E7
protein, the reaction proceeds to an oligomer, but of larger size,
more heterogeneous, and ultimately leading to large insoluble
material of ,2 nm under stirring conditions (Figure 6B, DLS).
The oligomeric product is also capable of binding of ThT and
Congo Red (not shown), confirming the b-sheet repetitive or
amyloid-like conformation. The kinetic reaction was followed by
fluorescence of ThT (Figure 6C) with a lag phase (,270 seconds)
similar to that observed for full-length E7, but with a slower
elongation phase that did not reach the plateau after ,150
minutes, in agreement with the overlapping subsequent slow
formation of an insoluble aggregate (Figure 6B).
In a previous work [15], we had shown that E7SOs are
spherical and homogeneous in size, as judged by electron
microscopy. We now analyze the oligomers using tapping mode
atomic force microscopy (AFM), and observed a homogenous
spherical population with a diameter ,19 nm for the full-length
protein (Figure 7A). The diameter measured by AFM is smaller
than that observed with electron microscopy [15], which can arise
from tip deformation, but it is consistent with DLS measurements
presented here (16.962.2 nm, Figure 2A).
Figure 4. Evaluation of cysteine blocking and Zn release effect on E7 conformation and oligomerization state. (A) Analysis of zinc
release from the high affinity coordination center of E7 followed at 500 nm by the formation of Zn(PAR)2 complex (black circles). The addition of
PMPS and DTT is indicated by arrows. Inset, size distribution profile of E7-PMPS measured by DLS. (B) CD spectrum of E7 (black line) and CD spectrum
of E7 upon addition of PMPS (dashed line).
doi:10.1371/journal.pone.0036457.g004
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EDTA show that the E7C oligomers have a worm-like amyloid
structures morphology with a contour-length of 50–150 nm
(Figure 7B). These results indicate that removal of zinc from the
E7C domain triggers the formation of oligomers but with different
characteristics from those of the full-length E7 protein. E7C
oligomers have inhomogeneous size and are the precursors of
worm-like amyloid structures while E7SOs have a spherical shape,
are homogenous in size and remain stable in solution.
Otherwise, the N-terminal domain of E7 has an intrinsically
disordered nature, it does not contain any metal, and we
previously showed that it is monomeric at 100 mM concentration
[19]. In addition, NMR experiments show that E7N is monomeric
at 3 mM concentrations (not-shown).
Discussion
The E7 oncoprotein from human papillomavirus is the major
transforming protein of the virus, with counterparts in other DNA
tumor viruses. We have been investigating its biochemical
Figure 5. Kinetics of E7SOs assembly at different initial E7
concentration. (A) The assemblies of E7SOs at the indicated protein
concentrations were monitored by ThT fluorescence. The rates of the
elongation phase were estimated from the slope of dashed lines. (B)
Determination of the nucleus size. Based on the KL model, the nucleus
size n is calculated by averaging four slopes obtained from the log-log
plots of the E7SOs versus E7 free molar concentration for different
single time points as described in material and methods. According to
this model, the observed nucleus size was 1.260.2. (C) Determination of
the reaction order of elongation phase. The reaction order of E7SOs
assembly was calculated of the power dependence of the rate of the
elongation phase with the E7 initial concentration. The slope of the log-
log plot 2.360.3 determines the elongation reaction as second order
reaction.
doi:10.1371/journal.pone.0036457.g005
Figure 6. Oligomerization properties of E7C. (A) CD spectra of
E7C (full line), E7C protein after 2 hours (broken and dotted line) and
overnight incubation (broken line) with EDTA. (B) Size distribution
measured by DLS. The distribution profiles correspond to: E7SOs (white
bars), E7C incubated 2 hours with EDTA (grey bars) and E7C incubated
24 hours with EDTA (black bars). (C) Kinetic measurement of the
oligomerization assembly after the addition of EDTA monitored by
Thioflavin T fluorescence. E7C oligomerization kinetic (black full line)
and E7SOs kinetic formation (grey full line). The time axis is in a log
scale.
doi:10.1371/journal.pone.0036457.g006
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role. The protein binds to a large number of cellular targets, and
this property lies largely on its structural plasticity arising from the
intrinsically disordered nature of its N-terminal domain, and in
fact, it turned out to be an excellent model for IDPs [17,18,19,43].
A salient feature was its ability to self-assemble into spherical
oligomers upon removal of a tetrahedrically coordinated zinc
atom, and we showed that these structures are formed within cell
lines and cancerous tissue [27].
The ability to form stable spherical and soluble oligomers with
amyloid-like properties, and the well known fact that such type of
oligomers are universal intermediates in amyloid pathways [44],
establishes it as a model for understanding general amyloid
intermediates assemblies. Moreover, spherical oligomers, not
insoluble fibers, are believed to be the more toxic species [1,45],
providing more interest to the challenge of dissecting its assembly
mechanism.
With this in mind, we made use of a number of different and
complementary spectroscopic and biophysical probes to under-
stand the complex polymer chemistry behind this mechanism. The
reaction starts from the addition of a metal chelator which
ultimately leads to oligomerization. The process is rather slow (no
events observed in experimental dead time), and involves changes
in secondary, tertiary and quaternary structure, with the presence
of a significant lag, followed by an elongation phase, ultimately
leading to a homogeneous spherical oligomer (E7SOs), with no
parallel soluble or insoluble routes.
For the analysis of the reaction, we used a kinetically controlled
model (KL) in order to define the parameters at each stage [28].
E7 is a weak dimer and exists in a fast pre-equilibrium with a
monomeric species. This species interacts with the chelator which
slowly and gradually reacts with the zinc atom, forming an
ensemble/collection of ternary E7-zinc-chelator complexes (‘‘pre-
nucleus intermediate’’), and replacing each of the thiolate bonds
present in the tetrahedrical coordination from the initial native
state of the protein. This slow process constitutes the lag phase
which terminates by the complete release of the zinc atom and the
generation of an apo-monomeric Z-nucleus, which grows gradu-
ally by sequential second-order additions of monomers into the
final E7SOs.
The evidence presented throughout the work indicates that the
Z-nucleus is rather structured, even though the native state of E7
must necessarily change drastically upon the removal of the
structural zinc atom. Moreover, even when all zinc-coordinated
cysteines are modified by the specific reagent PMPS, the assembly
does not take place, strongly suggesting that a partially folded
intermediate conformation is required and that the cysteine
residues either participate in assembly [46] or the latter is sterically
hindered by the presence of the PMPS moiety. In support to this,
this species is able to readily recapture free zinc upon removal of
the cysteine modifier.
By showing that the zinc-containing globular C-terminal
domain alone can self-assemble, we demonstrate that the
oligomerization determinant lies within this domain. However,
the process is not identical to the full-length protein, as the E7C
oligomers are heterogeneous and ultimately lead to insoluble
aggregation, by forming worm-like structures, similar to those
observed in amyloid routes [47]. Therefore, this modular
oncoprotein oligomerizes by its C-terminal domain and requires
its N-terminal intrinsically disordered domain to avoid undergoing
irreversible aggregation into worm-like amyloid structures. This
domain is highly acidic, and bears several interaction sites,
including its main target retinoblastoma, as well phosphorylation
and potential PEST degradation site, and these remain exposed to
the milieu. A picture emerges of a structured core (E7C)
surrounded by a dynamic/fluctuating IDD (E7N). In the complex
environment of the cell, and given the fact that it can interact with
such a large number of targets, we hypothesize that E7 is likely to
form hetero-oligomers [27]. Moreover, we had shown that E7SOs
display non-specific chaperone holdase activity [16]. Figure 8
integrates the main features of the two oligomerization mecha-
nisms, stressing how the presence of the E7N IDD prevents the
progression into an amyloid route.
The present work dissects the self-assembly mechanism of a
model viral oncoprotein with IDP properties. Interestingly, the
work goes beyond the role of the functional assembly of this
oncoprotein and provides insights into different biological and
chemical processes. The first series of implications relates to
polymer assembly. A fragment as small as 5 kDa undergoes high
efficiency and high fidelity ordered self-assembly, triggered by the
removal of a structural zinc, which nevertheless does not lead to
unfolding or aggregation.
An interesting conclusion is that a similar assembly mechanism
holds for viral capsids, thought to be very symmetrical and regular
structures [29]. Most importantly, spherical self-assemblies are at
Figure 7. Atomic force microscopy. (A) Visualization of E7SOs. The
xy scale corresponds to 1 mm. (B) Visualization of E7C treated with EDTA
for 2 hours. The xy scale corresponds to 1 mm. The white square inset
indicates the zoom region.
doi:10.1371/journal.pone.0036457.g007
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toxic species) in the formation of amyloid fibers.
An ordered self-assembly triggered by zinc removal make us
wonder how this takes place within the cellular environment. We
have defined controlled ‘‘artificial’’ experimental conditions of
temperature, pH, protein and chelator concentration, but we can
speculate about the ‘‘natural’’ conditions. An obvious one is the
concentration, which is affected by the balance between synthesis
and degradation, but also influenced by molecular crowding. Since
free zinc concentration in cells is minimal, the process could be
assisted by a metal removing protein such as metallothioneins or
metal chaperones [48]. Given that we have shown that the
oligomers exist in their natural host cells in high levels specifically
within the cytosol, the self-assembly event would then be
modulated by a cellular zinc chelator, providing a regulatory role
to this particular zinc, beyond its structural role in stabilizing a
particular non-oligomeric fold.
In summary, this modular partly intrinsically disordered viral
oncoprotein undergoes an ordered self-assembly mechanism that
shares fundamental features with other natural macroassemblies
such as viral capsids and amyloid intermediates, can take place
and could be modulated within cells, and provide a platform for
nanotechnological applications. Some of these include novel
scaffolds for therapeutic applications such as self-assembly peptides
used in biomaterials for regenerative medicine [49] or slow release
of cytokines [50]. In fact, we have recently demonstrated that the
E7SOs can be used as therapeutic vaccine candidates for HPV
related neoplasic lesions [51].
Materials and Methods
Proteins Expression and Purification
Recombinant E7 HPV-16 protein was expressed and purified as
previously described [17]. The E7 HPV-16 C-terminal domain,
spanning residues 40–98, was expressed and purified as previously
described [52].
Circular Dichroism (CD)
Far-UV CD measurements were carried out on a Jasco J-810
spectropolarimeter using a Peltier temperature-controlled sample
holder at 25uC in a 0.1 cm path length cell with a protein
concentration of 15 mM. All the measurements were performed at
10 mM sodium phosphate pH 7.0 and 1.0 mM DTT. Assembly
kinetics were followed by monitoring at 202 nm and 216 nm.
Fluorescence Measurement
Fluorescence measurements were performed using a Jasco J
spectrofluorimeter (Nikota Japon). In order to compare the
changes in the fluorescence intensity during assembly at different
protein concentration, the photomultiplier voltage and the
emission and excitation band pass were kept constant in the
measurement of different protein concentrations samples. All the
measurements were performed at 10 mM sodium phosphate
pH 7.0 and 1 mM DTT. The ThT assays at different protein
concentrations were performed keeping ThT concentration
constant at 20 mM. ThT kinetics were followed at 490 nm and
446 nm emission and excitation wavelength respectively. The
ANS fluorophore was used at 60 mM, and the kinetic was carried
out at 463 nm emission and 370 nm excitation wavelength.
Kinetics following Tyr fluorescence were carried out at 305 nm
emission and 280 nm excitation wavelength. In all cases, the
starting point corresponds to the addition of EDTA or TPEN
chelator.
Nucleus Size Calculation
In the KL model, the relationship between the concentration of
the E7SOs and the free protein at a certain time during the
assembly is given by the equation 1: [E7SOs]=k*[E7free]
n. This
relationship is valid in the time interval, after the lag phase and
before reaching the steady state. In the equation 1, k is a
proportionality constant and n reports the nucleus size. The
nucleus size n is calculated from the slope of a log-log plot of
E7SOs and E7 free molar concentration. Each straight line was
obtained calculating the E7SOs and E7 free concentrations
obtained at a single time for different initial total protein
concentrations. E7 free concentration is monomeric concentra-
tion. This model was applied in the ThT fluorescence kinetics at
different protein concentrations. The ThT fluorescence signal is
proportional to the E7SOs assembly: [E7SOs],ThT signal. The
free protein was taken from: [E7free],[E7]initial*(1-ThTsignal)
[28].
Figure 8. Schematic representation of E7SOs self-assembly route and amyloid route on E7C. The scheme shows the hallmarks features of
the E7SOs assembly, including the slow z-nucleus formation phase and the second order polymerization reaction. E7C that contain the assembly
domain but is devoid of the IDD N-terminal region is prone to form worm-like structures.
doi:10.1371/journal.pone.0036457.g008
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DLS measurements were carried out on Zetasizer Nano S DLS
device from Malvern Instruments (Malvern). Measurements were
performed in 10 mM sodium phosphate pH 7.0 and 1.0 mM
DTT. E7 and E7C were filtrated with Ultrafree-MC microcen-
trifuge filters 0.22 mm Millipore before measurements were done.
E7 and E7C protein concentration were kept at 15 mM. The
temperature was maintained at 25uC by Peltier control system.
Results were processed employing the software package included
in the equipment. All the points in the kinetics assay were carried
out by averaging a set with 6 measurements duration 10 seconds
each one and the delay between set was 60 seconds.
PAR-PMPS Assay
Briefly, 600 mM of the mercurial reagent PMPS was added to
10 mM of E7 dimer, leading to the release of Zn. The secondary
structure of PMPS modified apo-E7 was evaluated by far UV CD
spectroscopy [53]. After incubated during 1 hour, DLS measure-
ment was performed to analyze the PMPS modified apo-E7
oligomerization state.
To confirm the Zn release from E7 protein upon PMPS
addition, we performed the same experiment but in presence of
100 mM PAR. PAR reagent form a complex with Zn that can be
quantified spectrophotometrically and the time trace of Zn (PAR)2
complex formation was obtained by recording absorbance at
500 nm. When indicated, PMPS and DTT were added to a final
concentration of 600 mM and 1.2 mM, respectively. As a control
experiment, we confirmed that the DTT concentration used does
not interfere with the formation of the PAR-Zn, as is expected
(Not shown).
Atomic Force Microscopy (AFM)
For AFM imaging, E7SOs and E7C were performed at 2 ng/
mL and 10 ng/mL respectively, in buffer containing 10 mM
HEPES pH 7.0 and 1.0 mM MgCl2. Ten microliters of the
sample was deposited onto freshly cleaved mica. After 5 minutes
the samples was gently washed with 1 mL of Milli-Q water to
remove molecules that were not firmly attached to the mica and
blow-dried with nitrogen. Tapping-mode AFM was performed
using a Nanoscope III Multimode atomic force microscope
(Digital Instruments, Veeco Metrology, Santa Barbara, CA) using
J-type piezoelectric scanner with maximal lateral range of 120 mm.
Microfabricated silicon cantilevers 125 mm in length with a force
constant of 40 N/m were used (Nano Devices, Veeco Metrology).
The images (512 pixels) were captured with a scan size between
0.5 and 3.0 mm at a scan rate of 1–2 scan lines. Images were
processed by flattering using Nanoscope software (Digital Instru-
ments), which was used to remove background noise. WsxM 4.0
beta 2.1 software was used to analyze the images.
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